TB-500

Plain-English version: TB-500 is a lab-made peptide modeled on the working part of a natural protein called thymosin beta-4 (Tβ4). Your body already makes Tβ4 — it is one of the most abundant peptides inside human cells, found in every cell type except red blood cells. When you get injured, Tβ4 is released and acts like a foreman on a construction site: it recruits repair cells, helps them crawl to the damaged area, and coordinates the rebuild.^[1]

TB-500 contains the key functional region of that protein, centered on a short sequence called the actin-binding domain (the amino acids LKKTETQ). This is the part responsible for the peptide's headline activities — promoting cell migration, supporting new blood-vessel formation, and dialing down inflammation.^[1] Thymosin beta-4 works by binding and regulating actin, the scaffolding protein that controls a cell's shape and ability to move. By managing the supply of usable actin, Tβ4 helps cells reorganize and travel to where repair is needed.^[1]

TB-500 vs. thymosin beta-4: an important distinction

These two names get used interchangeably, but they are not identical, and the difference matters for how you read the evidence:

• Thymosin beta-4 (Tβ4): the full-length, 43-amino-acid natural peptide. This is the molecule that has been studied in human clinical trials — but as a topical product (eye drops and a skin formulation), not as an injection for injuries.^[6]
• TB-500: the synthetic version sold as a research chemical for injection. Almost all of the muscle-and-tendon research people cite when buying TB-500 was done with Tβ4 or its active fragment in animals, not with injectable TB-500 in humans.^[5]

So when a seller shows you "clinical trial" language, ask which molecule, which route, and which species. For the injury-recovery use that TB-500 is famous for, the honest answer is: animal and cell studies only. We cover this in depth in the benefits section, and side-by-side in our thymosin beta-4 vs TB-500 comparison.

Legal and regulatory reality

TB-500 is not FDA-approved for any indication. It has no registered FDA clinical trials and no entry in the FDA's approved-drug database, and the FDA has stated it has not identified human exposure data for drug products containing the thymosin beta-4 LKKTETQ fragment. The parent molecule (as a topical ophthalmic drug called RGN-259) has advanced through Phase 2/3 eye trials and holds FDA Fast Track status, but it has not received marketing approval.^[6][7] Thymosin beta-4 / TB-500 is also on the World Anti-Doping Agency (WADA) Prohibited List under category S2, so it is banned in tested sport. See Are Peptides Legal? for the full breakdown.

The one-sentence takeaway: TB-500's active region grabs and releases actin — the protein that lets cells change shape and move — which in turn lets repair cells migrate to an injury, build new blood vessels, and calm inflammation. Below is the evidence layer by layer, with an honest note each time on whether it came from a test tube, an animal, or a human.

1. Actin sequestering and cell migration (well documented, lab/animal)

The best-characterized mechanism is actin sequestering. Thymosin beta-4 is the major intracellular "actin buffer" — it binds monomeric actin (G-actin) and holds it in reserve. The LKKTETQ domain is what drives this. By managing the pool of available actin, Tβ4 controls how quickly cells can build and dismantle their internal scaffolding, which is the physical basis of cell crawling.^[1] Reviews describe Tβ4 as an actin-sequestering protein that "moonlights" as an extracellular signal to repair injured tissue, promoting migration of the cells that rebuild skin, blood vessels, and other tissues.^[1][2]

2. Angiogenesis — new blood vessel formation (animal/in vitro)

Healing tissue needs blood supply to deliver oxygen and nutrients. In laboratory and animal work, thymosin beta-4 promoted angiogenesis (the growth of new blood vessels) alongside dermal wound healing and even hair-follicle development.^[3] This is a preclinical finding — it has not been demonstrated in a human injury trial — but it is a plausible reason the peptide supports repair across several tissue types.

3. Anti-inflammatory signaling (preclinical)

Reviews of thymosin beta-4 describe anti-inflammatory activity as part of its tissue-repair toolkit — reducing the inflammatory signaling that, when it drags on too long, keeps a wound stuck in the damage phase instead of progressing to rebuild.^[2] Again, this is characterized in cell and animal models, not human trials.

4. Muscle repair: recruiting the cells that rebuild muscle (animal/cell)

This is the mechanism most relevant to TB-500's popularity. When muscle is injured, the body produces thymosin beta-4 locally, and it acts as a chemoattractant — a chemical "come here" signal — that recruits myoblasts (the precursor cells that fuse to form new muscle fibers) to the site of damage.^[5] This gives a genuine mechanistic basis for the muscle-recovery use case. But read the limitation carefully: it is a mechanistic, animal/cell study. It shows how Tβ4 could help muscle heal; it is not a human efficacy trial showing that injecting TB-500 makes people recover faster.

5. Cardiac repair (mouse, preclinical — do not over-read)

In a widely cited mouse study, after the coronary artery was tied off to simulate a heart attack, thymosin beta-4 boosted the activity of integrin-linked kinase (ILK) and Akt in the heart, improved early survival of heart-muscle cells, and improved cardiac function.^[4] This is real and interesting, but the results are qualitative in mice, with no reported infarct-size percentages, and they absolutely do not translate into a claim that TB-500 treats human heart attacks. Treat it as biology-of-interest, not as guidance for a cardiac condition.

Bottom line on mechanism

The how it could work story for TB-500 is scientifically solid and consistent across multiple independent research groups. The gap is the does it work in humans, by injection, for injuries question — which has not been tested. Keep those two things separate whenever you read marketing copy.

Read this first: the benefits below are framed the way real research supports them — plain-English claim, then the mechanism, then which population was actually studied, then how strong the effect was, then the limitation. For TB-500 the recurring limitation is the same one: the promising data is preclinical (animals and cells), and the only human trials used a different molecule and route (topical eye drops of the parent thymosin beta-4). We are not going to pretend otherwise.

Tissue repair and wound healing

Claim: TB-500 may accelerate repair of skin, muscle, tendon, and other soft tissue. Mechanism: the active fragment promotes cell migration (via actin regulation) and angiogenesis, bringing repair cells and blood supply to the injury.^[1][3] Population studied: rodents and cultured cells. Effect: animal studies of thymosin beta-4 showed promotion of dermal wound healing and angiogenesis.^[3] Limitation: no human wound-healing trial of injectable TB-500 exists; effect sizes in humans are unknown.

Muscle recovery

Claim: TB-500 supports muscle recovery after injury. Mechanism: injury-induced thymosin beta-4 recruits myoblasts (muscle-precursor cells) to the damaged site.^[5] Population studied: animal/cell models. Effect: demonstrated chemoattraction of myoblasts — a plausible driver of faster muscle repair. Limitation: this is a mechanism paper, not a controlled human recovery trial. Human dosing, timing, and real-world benefit are not established.

Tendon, ligament, and connective-tissue healing

Claim: TB-500 aids tendon and ligament recovery and may help remodel scar tissue and adhesions. Mechanism: the same cell-migration and angiogenesis pathways that support general tissue repair.^[1][2] Population studied: preclinical and heavy real-world use in veterinary medicine, especially equine (racehorse) tendon and ligament injuries. Effect: widely used in horses, which has produced a large body of anecdotal and veterinary experience. Limitation: veterinary and anecdotal use is not the same as controlled human evidence. There are no human tendon/ligament efficacy trials.

Anti-inflammatory support

Claim: TB-500 reduces inflammation at injury sites, allowing cleaner healing with less scarring. Mechanism: thymosin beta-4's documented anti-inflammatory signaling as part of its repair program.^[2] Population studied: cell and animal models. Effect: described qualitatively in reviews. Limitation: not quantified in humans. For other anti-inflammatory peptides, see KPV and BPC-157.

Cardiac repair (research interest only)

Claim: thymosin beta-4 may protect and repair heart tissue. Mechanism: ILK/Akt activation, improved cardiomyocyte survival, and better cardiac function after simulated heart attack.^[4] Population studied: mice. Effect: qualitative functional improvement; no infarct-size figures reported. Limitation: mouse data only. This is not a reason to use TB-500 for any heart condition — do not self-treat cardiac issues with a research peptide.

The one place there IS human data — and why it doesn't validate the injury use

The parent molecule has real human trial data, but for something completely different: dry eye, as a topical drop. In a Phase 2 randomized, placebo-controlled trial, 9 patients with severe dry eye used topical thymosin beta-4 ophthalmic solution (RGN-259 0.1%) six times a day for 28 days. Compared with the vehicle (inactive) drops, the active group had a 35.1% reduction in ocular discomfort (P=0.0141) and a 59.1% reduction in total corneal fluorescein staining (a measure of eye-surface damage; P=0.0108) by day 56.^[6] A companion Phase 2 trial using a controlled adverse-environment model reported supporting tolerability and efficacy signals.^[7]

Why this does not prove the injury use: it is a tiny study (9 patients), a different formulation (a topical eye drop, not an injection), and a completely different target (the eye surface, not muscle or tendon). It is genuine evidence that the parent peptide can do something measurable in humans — but it cannot be used to claim that injecting TB-500 heals sports injuries. Anyone who cites the dry-eye trials as proof of injectable musculoskeletal benefit is misusing them.

Honest summary of the evidence

• Strong: the biological mechanism (actin sequestering, cell migration) in lab and animal models.
• Moderate/preclinical: wound healing, angiogenesis, muscle-cell recruitment, cardiac protection — all animal or cell studies.
• Human: only topical dry-eye data for the parent molecule. Nothing for injectable TB-500 in injury recovery.

If you want a peptide with a larger (still preclinical) research base for musculoskeletal and gut healing, compare against BPC-157 — see our full BPC-157 vs TB-500 comparison.

Critical honesty note: no published human trial has established an injectable TB-500 dose for injury or muscle repair. The protocol below is what the research and community use — it is anecdotal and not clinically validated. The only human dosing evidence that exists is for a different product entirely (topical RGN-259 0.1% eye drops), which tells you nothing about how much to inject. Treat the table as a description of common practice, not a medical recommendation.

Common community protocol (anecdotal, not trial-derived)

Phase	Typical dose	Frequency	Duration	Purpose
Loading	2–2.5 mg	2× per week	4–6 weeks	Build up systemic tissue levels
Maintenance	2–2.5 mg	1× per week or biweekly	4–8 weeks as needed	Sustain repair support

A full cycle therefore runs roughly 8–14 weeks. TB-500 is dosed less frequently than most peptides because thymosin beta-4 is thought to have a relatively long tissue residence, and because it acts systemically rather than at one site. That systemic action is why the community view is that injection location does not need to be at the injury — a standard subcutaneous injection into the abdominal fat pad is the usual technique.

Reconstitution with a worked example

TB-500 ships as a lyophilized (freeze-dried) powder, usually in 2 mg or 5 mg vials. You rehydrate it with bacteriostatic water (BAC water) before drawing a dose. The math is just: concentration = total mg ÷ mL of water added, then volume to draw = desired dose ÷ concentration.

Worked example (5 mg vial):

• Add 2 mL BAC water to a 5 mg vial → concentration = 5 mg ÷ 2 mL = 2.5 mg/mL.
• To draw a 2.5 mg dose: 2.5 mg ÷ 2.5 mg/mL = 1.0 mL, which is 100 units on a standard U-100 insulin syringe.
• To draw a 2 mg dose from the same vial: 2 mg ÷ 2.5 mg/mL = 0.8 mL = 80 units.

Worked example (2 mg vial): add 1 mL BAC water → 2 mg/mL; draw the full 1 mL (100 units) for a 2 mg dose.

Use the peptide calculator to confirm your volumes, and the reconstitution guide for sterile step-by-step technique (wipe the stopper, run the water slowly down the inside wall, swirl gently, never shake).

Timing, cycles, and stacking

• Time of day: no strict requirement — thymosin beta-4 is not tied to a circadian rhythm, so any consistent time works.
• Relative to injury: community protocols often begin as soon as reasonable after an injury, on the logic that repair signaling is most useful early.
• Cycle length: loading (4–6 weeks) plus maintenance (4–8 weeks) = about 8–14 weeks total.
• Stacking: most commonly paired with BPC-157. The rationale is complementary mechanisms — TB-500 for broad systemic repair, BPC-157 for localized healing and angiogenesis. See the Healing Stack for the combined protocol.

Storage

• Lyophilized (unmixed): −20°C for long-term storage; 2–8°C is fine for months.
• Reconstituted: keep refrigerated at 2–8°C and use within about 28 days.
• Avoid repeated freeze-thaw cycles and protect from light.

See the full peptide storage guide for details.

Plain-English takeaway: in animal studies and anecdotal human use, TB-500 is usually described as well tolerated with mild, short-lived side effects. But be clear-eyed about the ceiling on that reassurance: there is no large-scale human safety data for injectable TB-500. The only controlled human safety information comes from the topical eye-drop trials of the parent molecule, which reported acceptable tolerability with no serious drug-related adverse events — but a topical eye drop does not tell you what a systemic injection does over months.^[6][7] For general context, see Are Peptides Safe?

Reported side effects (anecdotal / preclinical)

Side effect	Frequency	Severity	Notes
Injection-site reactions	Common	Mild	Redness, irritation, or bruising — standard subcutaneous injection effects
Head rush / lightheadedness	Occasional	Mild	Transient, shortly after injection
Lethargy / fatigue	Occasional	Mild	Reported in the first days; usually settles
Headache	Occasional	Mild	More often during the loading phase; typically resolves
Nausea	Occasional	Mild	More likely at higher doses

These reports come from animal research and self-reported human use, not controlled trials, so both the frequencies and the reassurance carry uncertainty. Product quality is a major confounder — some reported reactions may come from contaminants, not the peptide itself (see Sourcing & Quality).

The theoretical cancer / angiogenesis concern

TB-500 promotes cell migration and angiogenesis. In theory, those same properties could support the blood supply and spread of an existing tumor, and thymosin beta-4 is known to be upregulated in some tumor microenvironments. Here is the honest framing: this concern is mechanistically plausible but not demonstrated — no study has shown that exogenous TB-500 causes cancer. It is a reason for caution, especially for anyone with a current or past malignancy, not an established danger. We present it as a theoretical risk, which is exactly what it is.^[2]

What we don't know

• No completed human trials of injectable TB-500 means human pharmacokinetics, long-term safety, and dose-response are unknown.
• No drug-interaction data exists.
• It has not been studied in pregnant or breastfeeding individuals.

Who should not use it

• Anyone with active cancer or a cancer history — because of the theoretical angiogenesis concern above.
• Pregnant or breastfeeding individuals — no reproductive safety data.
• Anyone with known hypersensitivity to thymosin peptides.
• Competitive, drug-tested athletes — thymosin beta-4 / TB-500 is on the WADA Prohibited List (S2). Using it will cause a positive doping test and sanctions.

What to do if something feels wrong

Stop dosing and seek medical care for anything beyond mild, transient effects — persistent headache, an allergic reaction (hives, swelling, difficulty breathing), or any symptom that concerns you. Bring the product and its lot number to any medical visit. Because this is an unapproved research compound with no antidote protocol, conservative caution is the right default.

How the safety picture compares to BPC-157

Both have favorable-looking preclinical profiles and share the theoretical angiogenesis-cancer concern. Neither has completed large human safety trials. TB-500 carries the extra strike of being WADA-banned. BPC-157 has a somewhat larger preclinical safety literature. See the full comparison.

Because TB-500 is an unregulated research compound, the biggest practical risk is often not the peptide's biology but what is actually in the vial. Purity, identity, and sterility vary enormously between suppliers, and there is no regulator checking. Treat sourcing as a core safety issue.

What a good product should come with

• Third-party Certificate of Analysis (COA): from an independent lab, not the seller's in-house sheet. It should show HPLC purity (look for ≥98%) and mass-spectrometry identity confirming the correct peptide.
• Batch-specific testing: the COA should reference the exact lot number you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended for injection.
• Proper packaging: lyophilized powder in a sealed, light-protected vial.

Red flags

• No COA, or a COA from the manufacturer rather than an independent lab.
• Pre-mixed liquid "TB-500" (much shorter shelf life and higher contamination risk than lyophilized powder).
• Prices far below the market — peptide synthesis has real costs; suspiciously cheap usually means under-dosed or impure.
• "For human use" labeling or explicit health claims — legitimate research suppliers label "not for human consumption," and human-use claims signal a non-compliant seller.

Legal status, plainly stated

• FDA: not approved for any use. Sold only as a research chemical labeled "not for human consumption." The parent molecule's topical eye-drop version (RGN-259) has Fast Track status but no marketing approval.^[6]
• Compounding — July 2026 recommendation: TB-500 is not on the FDA's 503A compounding list, but on July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend adding it, over the objection of FDA staff who found no supporting human trials. The vote is non-binding and does not make TB-500 legal to compound; FDA rulemaking would still be required, and that process has historically taken years rather than months. See our July 2026 FDA peptide panel vote report.
• Sport: banned by WADA (S2 category) — prohibited at all times in tested sport.
• Controlled-substance status: not a DEA-scheduled controlled substance; possession is not criminalized, but that is not the same as being approved or safe.

For the complete legal picture, see Are Peptides Legal?

TB-500 is rarely discussed in isolation. Here is how it lines up against the peptides it is most often compared to.

TB-500 vs. BPC-157

Factor	TB-500	BPC-157
Core mechanism	Actin sequestering, cell migration, angiogenesis	VEGF-driven angiogenesis, NO-system modulation, growth factors
Best framed for	Broad systemic repair, muscle recovery	Localized injuries (tendon, joint), gut healing
Route	Injection only	Injectable or oral (gastric-acid stable)
Typical dosing	2–2.5 mg, ~2×/week	250–500 mcg daily
Human trials for injury use	None (animal/cell only)	None (animal/cell only)
Synergy	Frequently combined — complementary mechanisms in the Healing Stack

Neither has human injury trials, so the choice comes down to mechanism fit and route preference. Full breakdown: BPC-157 vs TB-500.

TB-500 vs. thymosin beta-4

TB-500 is the synthetic, injectable research version built around the active fragment; thymosin beta-4 is the full-length natural molecule and the one that actually reached human clinical trials — but only as a topical product for eye conditions.^[6] If someone points to "clinical evidence" for TB-500, this is the distinction to check. See thymosin beta-4 vs TB-500.

Research-grade TB-500 is typically sold in 5 mg or 10 mg vials. Because the community dose is measured in milligrams (2–2.5 mg) rather than the micrograms used for many peptides, a vial is consumed faster than, say, a BPC-157 vial — a 5 mg vial is roughly two loading doses.

Budget for the peptide plus consumables: bacteriostatic water, alcohol swabs, and insulin syringes. Since TB-500 is often stacked with BPC-157, many people price the two together, and some suppliers sell pre-mixed blends. A blend simplifies dosing but removes your ability to adjust each compound independently, and it makes a clean COA harder to verify — a real trade-off given the sourcing risks above. Prices shift constantly and vary by supplier and purity, so weigh cost against COA quality rather than chasing the lowest sticker price.